Most cases (22) are a rare coagulation disease called cerebral venous sinus thrombosis. Eight patients saw other types of thrombosis with low levels of platelets, which helped blood clot.
The British regulator said there were no reports of blood clots in the Pfizer-BioNTech vaccine, adding: "We are conducting a full review of these reports."
However, MHRA CEO Dr. June Raine emphasized that the benefits far outweigh any risks. She said: "Citizens should be invited to continue vaccinating."
Europe update expectations
Both the MHRA and the European Medicines Agency (EMA) stated that a causal relationship has not yet been established between coagulation cases and the AstraZeneca vaccine.
However, growing concerns have prompted some countries to suspend the introduction of the vaccine or restrict it to the elderly due to the relatively young people suffering from blood clots.
The Netherlands had five new cases among young women on Friday, and after one of them died, the AstraZeneca poking vaccine for people under the age of 60 was stopped.
After 31 cases of blood clots occurred, Germany has stopped using the vaccine for people under 60 years of age, most of whom are young and middle-aged women.
Many other countries, including France, have set similar age restrictions, while Denmark and Norway have suspended all vaccines.
Like the AstraZeneca vaccine previously announced by the World Health Organization, the European Medicines Agency (EMA) is expected to release its latest recommendations on this issue on April 7.
It said Wednesday that there are 62 cases of cerebral venous sinus thrombosis worldwide, of which 44 have occurred in the European Economic Area, which includes the European Union, Iceland, Liechtenstein and Norway.
However, this figure does not include all cases in Germany.
The area has managed more than 9.2 million AstraZeneca jabs.
EMA said it believes the vaccine is safe, and experts have not found specific risk factors such as age, sex or medical history.
"Weight of Evidence"
Paul Hunter, a medical microbiologist at the University of East Anglia in the United Kingdom, told AFP that he initially believed that the link between vaccination and blood clots was probably a "random link."
He said that as more and more evidence appeared in different countries, "more and more evidence now shows that Oxford AstraZeneca is actually the cause of these adverse events."
He said that despite this, the risk of death without the Covid vaccine was "greatly increased."
An AstraZeneca spokesperson told AFP that patient safety is its "highest priority."
She said that the UK, EU, and World Health Organization regulators have concluded that these benefits "substantially exceed the risks of all adult age groups."
AstraZeneca conducted an efficiency test in the United States last month and stated that its vaccine can effectively prevent 76% of the disease. It also said that data from the European Union and the United Kingdom showed no increased risk of blood clots.
The UK has used Oxford-AstraZeneca and Pfizer-BioNTech to administer more than 31 million first doses of the vaccine. People cannot choose the one they get.
The UK ordered 100 million doses of the Oxford-AstraZeneca vaccine in June 2020 and supported its development. In the same year, it also ordered 30 million doses of Pfizer-BioNTech vaccine.
(Except for the title, this story has not been edited by NDTV staff, but has been published through a joint feed.)